Xilio Therapeutics, Inc.
Data quality: 100%
XLO
Nasdaq
Manufacturing
Chemicals
$8.55
▼
$0.14
(-1.61%)
Mkt Cap: 49.44 M
Price
$8.55
Mkt Cap
49.44 M
Day Range
$8.55 — $8.68
52-Week Range
$6.47 — $16.52
Volume
7,721
Open $8.68
50D / 200D Avg
$7.91
8.06% above
50D / 200D Avg
$9.57
10.65% below
Quick Summary
Key Takeaways
Negative free cash flow of -5.51 M
Capital efficient — spends only 1.18% of revenue on capex
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)589.88%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROIC-42.02%
Net Margin-80.05%
Op. Margin-95.92%
Safety
Debt / Equity
N/A
Current Ratio2.20
Interest CoverageN/A
Valuation
PE (TTM)
-1.41
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.4 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.4 |
| Net Margin % | -80.1 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 589.88% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 43.77 M | Net Income (TTM) | -35.04 M |
| ROE | N/A | ROA | -26.19% |
| Gross Margin | N/A | Operating Margin | -95.92% |
| Net Margin | -80.05% | Free Cash Flow (TTM) | -5.51 M |
| ROIC | -42.02% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.20 |
| Interest Coverage | N/A | Asset Turnover | 0.33 |
| Working Capital | 67.69 M | Tangible Book Value | -8.10 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.41 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 1.13 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -11.14% | ||
| Market Cap | 49.44 M | Enterprise Value | -54.32 M |
| Per Share | |||
| EPS (Diluted TTM) | -4.19 | Revenue / Share | 7.57 |
| FCF / Share | -0.95 | OCF / Share | -0.86 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 1.18% | FCF Conversion | 15.73% |
| SBC-Adj. FCF | -11.09 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 43.77 M | 6.34 M | — | — | — |
| Net Income | -35.04 M | -58.24 M | -76.40 M | -88.22 M | -75.80 M |
| EPS (Diluted) | -4.19 | -1.09 | -2.78 | -3.22 | -13.52 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -41.98 M | -60.58 M | -79.13 M | -89.15 M | -75.04 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 56.04 M | 41.21 M | 52.14 M | 59.20 M | 51.19 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 1.54 M | 1.64 M | 1.90 M | 1.85 M | 1.50 M |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 154.69 M | 71.08 M | 60.93 M | 139.17 M | 218.06 M |
| Total Liabilities | 119.41 M | 53.48 M | 24.10 M | 33.52 M | 32.63 M |
| Shareholders' Equity | 35.27 M | 17.60 M | 36.83 M | 105.65 M | 185.43 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 137.53 M | 55.29 M | 44.70 M | 120.39 M | 198.05 M |
| Current Assets | 145.03 M | 60.23 M | 48.13 M | 124.50 M | 202.52 M |
| Current Liabilities | 56.27 M | 27.26 M | 15.96 M | 21.12 M | 12.78 M |
{"event":"ticker_viewed","properties":{"ticker":"XLO","listing_kind":"stock","pathname":"/stocks/xlo","exchange":"Nasdaq","country":"US"}}